Thomas John Dietz - 23 Jan 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role: Director
Signature: /s/ Thomas J. Dietz
Issuer symbol: N/A
Transactions as of: 23 Jan 2023
Net transactions value: +$71,580
Form type: 4
Filing time: 25 Jan 2023, 19:54:15 UTC
Previous filing: 27 Dec 2022
Next filing: 09 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Purchase	$71,580	+50,000		$1.43	50,000	23 Jan 2023	By Trust	F1, F2
holding	EIGR	Common Stock						21,000	23 Jan 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
F2	These shares are held directly by the Dietz Family Trust, for which the reporting person and his spouse serve as co-trustees.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

These shares are held directly by the Dietz Family Trust, for which the reporting person and his spouse serve as co-trustees.